Kodiak Sciences, Inc. (KOD)

Kodiak Sciences' stock has shown significant momentum, delivering a 311% return over the past year, with a share price of $14.88 as of October 15, 2025. JPMorgan upgraded Kodiak Sciences from "Neutral" to "Overweight" and raised its price target from $15.00 to $24.00, citing the de-risked potential of KSI-101. LifeSci Capital initiated coverage with an "Outperform" recommendation and a price target of $40.00. Chardan Capital maintained a "Neutral" rating with a $14.00 price target. Barclays upgraded its rating from "Underweight" to "Equalweight" and raised the price target from $7.00 to $17.00, following promising data from the Phase 2 BARDENAS trial. Jefferies initiated coverage with a "Buy" rating and a $15.00 price target. H.C. Wainwright maintained a "Neutral" rating but raised its price target from $3.00 to $5.00 after new data from the Phase 1b APEX study showed promising results for KSI-101. Clinical trial updates for KSI-101 and financial results have been key drivers.

There is no specific information available regarding the demand seasonality for Kodiak Sciences, Inc.'s products and services. As a clinical-stage biopharmaceutical company, its revenue generation is primarily through strategic collaborations and licensing agreements, rather than direct product sales to consumers, which would typically exhibit seasonality.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases, utilizing its proprietary Antibody Biopolymer Conjugate (ABC) Platform to enhance ophthalmic therapies. Their lead product candidate, tarcocimab tedromer (KSI-301), has completed Phase 3 clinical studies for retinal vascular diseases. Other pipeline products include KSI-501, an anti-interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for retinal vascular diseases, and KSI-101 (also referred to as KSI-501P or Tabirafusp Alfa), an unconjugated bispecific protein targeting IL-6 and VEGF, which is in Phase 3 clinical trials for macular edema secondary to inflammation (MESI).

Kodiak Sciences, Inc. is headquartered in Palo Alto, California, and conducts clinical trials primarily in the United States, with additional international sites to support global patient enrollment.

Information specifically detailing Kodiak Sciences' brand reputation in the past year is limited. However, the company's focus on innovation in retinal medicines and positive analyst upgrades contribute to a favorable perception within the investment and scientific communities.

Kodiak Sciences Inc. has a mixed ownership structure, with institutional investors holding the largest portion. Institutional investors collectively own approximately 87.17% of the company, while insider ownership stands at 2.28%, and retail investors hold about 10.55% of outstanding shares. Major institutional shareholders include Baker Bros. Advisors LP, BlackRock, Inc., Adage Capital Partners Gp, L.l.c., Acadian Asset Management Llc, Vanguard Group Inc, ICONIQ Capital, LLC, TCG Crossover Management, LLC, and State Street Corp. Victor Perlroth, the CEO and Chairman of the Board, is also a significant individual shareholder.